Cardiometabolic consequences of Hereditary Fructose Intolerance

Cardiometabolic consequences of Hereditary Fructose Intolerance - HFI study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON43427

Enrollment

Registered

2016-04-25

Start date

2016-07-06

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hereditary fructose intolerance (genetic fructose intolerance)

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Age * 18 years Diagnosis HFI (with the exception of the control groups)

Exclusion criteria

Exclusion criteria: Inability to give informed consent Contraindications for MRS (i.e. claustrophobia, heart pacemaker or other electronic appliances implanted in the body, history of collapse or seizures, or pregnancy

Design outcomes

Primary

Measure	Time frame
- Degree of hepatic fat accumulation in patients with HFI and age, sex and BMI matched controls.	—

Secondary

Measure	Time frame
- Degree of hepatic fibrosis in patients with HFI and age, sex and BMI matched controls. - Lactate response to an oral glucose tolerance test in patients with HFI and age, sex and BMI matched controls. - Changes in fingerpressure during peripheral applanation tonometry in patients with HFI and age, sex and BMI matched controls. - Changes in skin blood flow during laser doppler flowmetry in patients with HFI and age, sex and BMI matched controls. - Carotid-femoral pulse wave velocity in patients with HFI and age, sex and BMI matched controls. - Plasma hepatokines in patients with HFI and age, sex and BMI matched controls, patients with glycogen storage disease 1a (GSD1a) and familial hypobetalipoproteinemia (FHBL). - Plasma lipids, biomarkers of low-grade inflammation and biomarkers of endothelial function in patients with HFI and age, sex and BMI matched controls, patients with GSD1a and FHBL. - Fat distribution (visceral and subcutaneous fat) in patients with HFI and age, sex and BMI matched controls. - 24 hours urinary fructose in patients with HFI and age, sex and BMI matched controls.	—

Measure

Time frame

- Degree of hepatic fibrosis in patients with HFI and age, sex and BMI matched controls. - Lactate response to an oral glucose tolerance test in patients with HFI and age, sex and BMI matched controls. - Changes in fingerpressure during peripheral applanation tonometry in patients with HFI and age, sex and BMI matched controls. - Changes in skin blood flow during laser doppler flowmetry in patients with HFI and age, sex and BMI matched controls. - Carotid-femoral pulse wave velocity in patients with HFI and age, sex and BMI matched controls. - Plasma hepatokines in patients with HFI and age, sex and BMI matched controls, patients with glycogen storage disease 1a (GSD1a) and familial hypobetalipoproteinemia (FHBL). - Plasma lipids, biomarkers of low-grade inflammation and biomarkers of endothelial function in patients with HFI and age, sex and BMI matched controls, patients with GSD1a and FHBL. - Fat distribution (visceral and subcutaneous fat) in patients with HFI and age, sex and BMI matched controls. - 24 hours urinary fructose in patients with HFI and age, sex and BMI matched controls.

—

Countries

Netherlands

Outcome results